Menarini Group Seeks EMA Approval for Obicetrapib Treatments for Cholesterol Management Menarini Group's request to EMA for the registration of Obicetrapib aims to provide new treatment options for patients with primary hypercholesterolemia. This could potentially enhance cholesterol management in patients unable to achieve target levels.

Menarini Group Seeks EMA Approval for Obicetrapib Treatments for Cholesterol Management #Italy #Florence #Menarini_Group #Obicetrapib #CETP_inhibitor

Menarini Group's Obicetrapib Gains EMA Review for Cholesterol Treatment Menarini Group's Obicetrapib, a CETP inhibitor, receives EMA consideration to treat hypercholesterolemia, potentially helping patients not meeting LDL goals.

Menarini Group's Obicetrapib Gains EMA Review for Cholesterol Treatment #Italy #Florence #Menarini_Group #Obicetrapib #CETP_inhibitor

Menarini Group's Obicetrapib Receives EMA's Review for Cholesterol Management The European Medicines Agency has accepted Menarini's application for Obicetrapib, a potential first-in-class CETP inhibitor, aimed at improving cholesterol management in adults.

Menarini Group's Obicetrapib Receives EMA's Review for Cholesterol Management #Italy #Florence #Menarini_Group #Obicetrapib #CETP_inhibitor